Summary of Study ST001660
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001065. The data can be accessed directly via it's Project DOI: 10.21228/M81Q3K This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST001660 |
Study Title | Plasmodium falciparum metabolomics as a result of treatment with putative acetyl-CoA synthetase inhibitors |
Study Summary | Plasmodium falciparum cells in culture were treated with respective compounds for 2.5 hours at 10xIC50 values. Metabolites were isolated using 90% methanol, dried, reconstituted in HPLC-grade water, and analyzed by HPLC/MS. Resulting data were analyzed and compiled to generate study data. |
Institute | Pennsylvania State University |
Department | Chemistry |
Laboratory | Llinás Laboratory |
Last Name | Llinás |
First Name | Manuel |
Address | W126 Millennium Science Complex, University Park, PENNSYLVANIA, 16802, USA |
mul27@psu.edu | |
Phone | 814-867-3444 |
Submit Date | 2021-01-22 |
Num Groups | 3 |
Total Subjects | 24 |
Raw Data Available | Yes |
Raw Data File Type(s) | mzXML |
Analysis Type Detail | LC-MS |
Release Date | 2021-06-01 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001065 |
Project DOI: | doi: 10.21228/M81Q3K |
Project Title: | Plasmodium falciparum metabolomics as a result of treatment with putative acetyl-CoA synthetase inhibitors |
Project Summary: | Plasmodium falciparum is the most virulent species of parasites that cause malaria. Current drug efforts that are used to combat this deadly disease often employ pharmacologic strategies that inhibit critical parasite metabolic functions. Compounds used in the present study have generated resistance mutations in major acetyl-CoA producing enzymes. Hence, we set out to test the metabolic effects of these compounds on Plasmodium falciparum parasites including those on acetyl-CoA production by treating parasites for 2.5 hours under 10xIC50 of the test compounds. We used a targeted HPLC/mass spectrometry-based approach to analyze parasite metabolism. We find that multiple compounds tested in these studies have led to relative decreases in acetyl-CoA abundance compared to control parasite conditions. These studies are necessary for understanding pharmacology effects on the most virulent human malaria parasite. |
Institute: | Pennsylvania State University |
Department: | Chemistry |
Laboratory: | Llinás Laboratory |
Last Name: | Llinás |
First Name: | Manuel |
Address: | W126 Millennium Science Complex, University Park, PENNSYLVANIA, 16802, USA |
Email: | mul27@psu.edu |
Phone: | 814-867-3444 |
Funding Source: | This work was supported by the Bill and Melinda Gates Foundation (OPP1054480) |
Subject:
Subject ID: | SU001737 |
Subject Type: | Cultured cells |
Subject Species: | Plasmodium falciparum |
Taxonomy ID: | 5833 |
Genotype Strain: | 3D7 |
Gender: | Not applicable |
Cell Counts: | 1x10^8 |
Factors:
Subject type: Cultured cells; Subject species: Plasmodium falciparum (Factor headings shown in green)
mb_sample_id | local_sample_id | Treatment |
---|---|---|
SA152026 | 20181008-Blank1 | Blank |
SA152027 | 20181008-Blank2 | Blank |
SA152028 | 20181008-Blank3 | Blank |
SA152029 | 20180815-Blank1 | Blank |
SA152030 | 20180815-Blank3 | Blank |
SA152031 | 20180815-Blank5 | Blank |
SA152032 | 20180815-Blank4 | Blank |
SA152033 | 20181008-Blank4 | Blank |
SA152034 | 20180815-Blank2 | Blank |
SA152035 | 20181008-Blank5 | Blank |
SA152036 | 20171106-Blank2 | Blank |
SA152037 | 20171106-Blank1 | Blank |
SA152038 | 20181220-Blank5 | Blank |
SA152039 | 20171106-Blank3 | Blank |
SA152040 | 20181220-Blank4 | Blank |
SA152041 | 20181220-Blank1 | Blank |
SA152042 | 20181220-Blank2 | Blank |
SA152043 | 20181220-Blank3 | Blank |
SA152044 | 20181008-MMV019721-3 | MMV019721 |
SA152045 | 20181008-MMV019721-1 | MMV019721 |
SA152046 | 20181008-MMV019721-2 | MMV019721 |
SA152047 | 20180815-MMV019721-3 | MMV019721 |
SA152048 | 20180815-MMV019721-2 | MMV019721 |
SA152049 | 20180815-MMV019721-1 | MMV019721 |
SA152050 | 20181220-MMV084978-2 | MMV084978 |
SA152051 | 20181220-MMV084978-1 | MMV084978 |
SA152052 | 20181220-MMV084978-3 | MMV084978 |
SA152053 | 20171106-MMV084978-2 | MMV084978 |
SA152054 | 20171106-MMV084978-3 | MMV084978 |
SA152055 | 20171106-MMV084978-1 | MMV084978 |
SA152056 | 20181220-ND1 | No treatment |
SA152057 | 20180815-ND3 | No treatment |
SA152058 | 20171106-ND3 | No treatment |
SA152059 | 20181220-ND2 | No treatment |
SA152060 | 20171106-ND2 | No treatment |
SA152061 | 20181220-ND3 | No treatment |
SA152062 | 20180815-ND1 | No treatment |
SA152063 | 20180815-ND2 | No treatment |
SA152064 | 20181008-ND3 | No treatment |
SA152065 | 20171106-ND1 | No treatment |
SA152066 | 20181008-ND2 | No treatment |
SA152067 | 20181008-ND1 | No treatment |
SA152068 | 20181220-QC3 | Pooled Parasite Samples |
SA152069 | 20181220-QC1 | Pooled Parasite Samples |
SA152070 | 20181220-QC2 | Pooled Parasite Samples |
SA152071 | 20181008-QC2 | Pooled Parasite Samples |
SA152072 | 20180815-QC3 | Pooled Parasite Samples |
SA152073 | 20180815-QC2 | Pooled Parasite Samples |
SA152074 | 20180815-QC1 | Pooled Parasite Samples |
SA152075 | 20171106-Pool3 | Pooled Parasite Samples |
SA152076 | 20171106-Pool2 | Pooled Parasite Samples |
SA152077 | 20181008-QC3 | Pooled Parasite Samples |
SA152078 | 20181008-QC1 | Pooled Parasite Samples |
SA152079 | 20171106-Pool1 | Pooled Parasite Samples |
Showing results 1 to 54 of 54 |
Collection:
Collection ID: | CO001730 |
Collection Summary: | Plasmodium falciparum 3D7 parasites were cultured in RPMI 1640 medium and magnetically enriched to increase the infected to uninfected RBC ratio. Following hemocytometer counts, 1x10^8 parasites were measured per condition into 5 mL of total media for 2.5 hours in the presence of drug. Medium was aspirated until 1 mL remained on each sample, the sample was transferred to a micro-centrifuge tube, spun, and the medium was aspirated. |
Collection Protocol Filename: | Metabolite_Extraction_for_LCMS_2017.pdf |
Sample Type: | Cultured cells |
Collection Location: | Millenium Science Complex, University Park, Pennsylvania |
Storage Conditions: | -80℃ |
Collection Vials: | 1.5 mL eppendorf |
Storage Vials: | 1.5 mL eppendorf |
Collection Tube Temp: | On ice |
Tissue Cell Quantity Taken: | 1x10^8 cells per sample in 1 mL total volume |
Treatment:
Treatment ID: | TR001750 |
Treatment Summary: | Plasmodium falciparum 3D7 parasites were cultured in RPMI 1640 medium and magnetically enriched to increase the infected to uninfected RBC ratio. Following hemocytometer counts, 1x10^8 parasites were measured per condition into 5 mL of total media for 2.5 hours in the presence of drug. No treatment or ND represents control parasites without additional alterations. Compounds (MMV...) are test compounds that were added at 10xIC50 value for the experimental duration. Blanks are sample tubes that follow the same procedures as samples following the quenching of metabolism. Both Pool and QC samples are combined samples of all samples from the analytical batch on that particular day. Dates in YYYYMMDD format are appended to individual samples to indicate the batch in which they were processed. |
Treatment Protocol Filename: | Metabolite_Extraction_for_LCMS_2017.pdf |
Treatment Compound: | MMV084978, MMV019721 |
Treatment Route: | Transfer to media by pipette |
Treatment Dose: | 10xIC50 |
Treatment Dosevolume: | 5 uL or less |
Treatment Doseduration: | 2.5 hours |
Treatment Vehicle: | DMSO |
Cell Storage: | Temperature and gas composition controlled incubator |
Cell Growth Container: | 6-well plate |
Cell Growth Config: | 5 mL in each sample well, 1x10^8 infected red blood cells per well, conditions performed in triplicate |
Cell Media: | RPMI 1640 containing Albumax, Gentamycin, Hypoxanthine, HEPES, Sodium Bicarbonate |
Sample Preparation:
Sampleprep ID: | SP001743 |
Sampleprep Summary: | Once samples were obtained, metabolism was quenched with 90% methanol containing 0.25 uM labeled aspartate, cells were centrifuged, and the supernatant was removed by nitrogen drying. Sample was reconstituted in 3% HPLC-grade methanol and run on the instrument. |
Processing Method: | Wash, spin, quench, spin, dry, store at -80 C until run on the instrument, resuspend |
Processing Storage Conditions: | On ice |
Extraction Method: | 90% methanol extraction |
Extract Cleanup: | Centrifugation and nitrogen drying |
Sample Resuspension: | 100 uL 3% methanol with 1 uM chlorpropamide |
Sample Spiking: | 0.25 uM Labeled Aspartate, 1 uM chlorpropamide |
Combined analysis:
Analysis ID | AN002711 |
---|---|
Analysis type | MS |
Chromatography type | Reversed phase |
Chromatography system | Thermo Dionex Ultimate 3000 |
Column | Waters XSelect HSS (100 x 2.1mm,2.5um) |
MS Type | ESI |
MS instrument type | Orbitrap |
MS instrument name | Thermo Q Exactive Plus Orbitrap |
Ion Mode | NEGATIVE |
Units | Normalized and blank subtracted peak area |
Chromatography:
Chromatography ID: | CH002000 |
Chromatography Summary: | Ion-pairing method using reverse-phase chromatography setup. |
Instrument Name: | Thermo Dionex Ultimate 3000 |
Column Name: | Waters XSelect HSS (100 x 2.1mm,2.5um) |
Column Temperature: | 30 |
Solvent A: | 97% water/3% methanol; 15 mM acetic acid; 10 mM tributylamine |
Solvent B: | 100% methanol |
Chromatography Type: | Reversed phase |
MS:
MS ID: | MS002508 |
Analysis ID: | AN002711 |
Instrument Name: | Thermo Q Exactive Plus Orbitrap |
Instrument Type: | Orbitrap |
MS Type: | ESI |
MS Comments: | Data was centroided using MSConvert and converted to .mzXML for utilization in MzMine and El-Maven software. |
Ion Mode: | NEGATIVE |